Epistem (AIM: EHP.L), the leading UK biotechnology and contract research company, has appointed Walbrook PR Ltd as part of its Financial PR and IR advisory team.
Walbrook's brief is to advise Epistem on its communications with Private Client Investment Managers in London and the Regions as well as other investors and Paul Cornelius, the new Head of IR at Walbrook, will lead the account. Walbrook will be working alongside Epistem's existing PR agency, De Facto Communications.
Epistem is a fast growing UK biotechnology and personalised medicine company commercialising its expertise in the areas of oncology, gastrointestinal diseases and dermatological applications. Epistem develops innovative therapeutics, biomarkers, and diagnostics, as well as providing contract research services to drug development companies. The Group's core expertise is focused on the regulation of adult stem cells located in epithelial tissue, which includes the gastrointestinal tract, skin, hair follicles, breast and prostate. Epistem does not conduct research in the areas of embryonic stem cells or stem cell transplantation.
Epistem listed on AIM in 2007 and operates three distinct business divisions:
- Contract Research Services
- Novel Therapies
- Personalised Medicine (Biomarkers and Diagnostics)
On 5 October 2010 Epistem announced results for the year ending 30 June 2010 with revenues up 45% to £5.74m and profit before tax of £0.35m (against a loss of £0.67m the previous year). EPS was up to 3.8p per share (2009: 1.1p). At the year end Epistem had strong cash reserves of £5.4m.
Epistem has also recently announced that its new handheld molecular diagnostic device, GenedriveTM, and it is currently undergoing beta testing in the US and UK.